Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK4 | Q13043 | 14/20 | 0.84 |
| ▸ | STK3 | Q13188 | 14/20 | 0.84 |
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295736 | 0.91 | STK4 (1.00) | STK4STK3LRRK2BRAFTNNI3K | |
| SCHEMBL31301542 | 0.86 | STK4 (1.00) | STK4STK3LRRK2 | |
| SCHEMBL30295810 | 0.85 | STK4 (1.00) | STK4STK3LRRK2BRAFTNNI3K | |
| SCHEMBL15401498 | 0.83 | LRRK2 (1.00) | STK4STK3LRRK2 | |
| SCHEMBL31301591 | 0.82 | STK4 (1.00) | STK4STK3LRRK2BRAFTNNI3K | |
| SCHEMBL31301726 | 0.80 | STK3 (0.72) | STK4STK3LRRK2BRAFTNNI3K | |
| SCHEMBL30295763 | 0.79 | STK4 (1.00) | STK4STK3LRRK2BRAFTNNI3K | |
| SCHEMBL4350720 | 0.78 | STK4 (0.68) | STK4STK3LRRK2BRAFTNNI3K | |
| SCHEMBL3539127 | 0.78 | STK4 (0.71) | STK4STK3LRRK2JAK2JAK3 | |
| SCHEMBL31301651 | 0.78 | STK3 (0.69) | STK4STK3LRRK2BRAFTNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | STK4 2/4885STK3 1/4885LRRK2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.